Categories Earnings, Retail

Cost optimization helps Dollar General post strong results in Q2

For the second quarter, Dollar General  Corporation (NYSE: DG) said its adjusted earnings rose to $1.74 per share compared to $1.52 per share in the year-over period, fuelled by more disciplined cost control measures as well as category management. The bottom-line was 17 cents higher than the Wall Street projection.

The adjusted earnings included certain legal expenses and after-tax impact.

For the second quarter, Dollar General  Corporation (NYSE: DG) said its adjusted earnings rose to $1.74 per share compared to $1.52 per share in the year-over period

Dollar General and its peer Dollar Tree (NASDAQ: DLTR) were slapped with fines amounting to $1.2 million on Monday for selling expired products. Both chains allegedly sold over-the-counter drugs that were expired, while Dollar General was penalized for selling obsolete motor oil that was not suitable for modern cars. 

Net sales for the second quarter rose 8.4% to $6.98 billion, vs $6.89 billion expected by the street. The top line was boosted by a 4% growth in same-store sales and positive sales contributions from new stores.

Except in the apparel category, same-store sales grew in all other units.

dollar general
Image courtesy: Dollar General

Dollar General has been investing in expanding and remodeling its stores, improving its assortment, as well as in other business growth initiatives.

DG shares rose 6.5% during pre-market trading on Thursday. Dollar General’s shares have gained 29% year-to-date.

READ: JCPenney reports 9% decline in comparable sales in Q2

Outlook

For the fiscal year 2019, Dollar General now expects net sales growth of approx 8%, compared to its previous expectation of 7%.  Growth in same-store sales is currently projected to be in the low-to-mid 3% range, compared to its previous expectation of about 2.5%.

Due to the legal expenses, adjusted EPS for this period is forecast to be $6.45 to $6.60.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top